Pro-Gly-Pro comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
=== Phrixotoxin-3 === Injection of this venom into mice causes immediate general ataxia, lack to response stimuli and semi-paralysis. Inability to stand and breathing reduction occurs within minutes. Flaccid paralysis and slowing of breathing eventually cause death (Bosmans 2006).
However, brief mitochondrial permeability transition pore openings play an essential physiological role in maintaining healthy mitochondrial homeostasis. Ciclosporin can induce a remission of proteinuria caused by such diseases as MCD and FSGS. Ciclosporin blocks the calcineurin-mediated dephosphorylation of synaptopodin, a regulator of Rho GTPases in podocytes, thereby preserving the phosphorylation-dependent synaptopodin-14-3-3 beta interaction. Preservation of this interaction, in turn, protects synaptopodin from cathepsin L-mediated degradation. Altogether, the antiproteinuric effect of Ciclosporin results, at least in part, from the maintenance of synaptopodin protein abundance in podocytes, which, in turn, is sufficient to maintain the integrity of the glomerular filtration barrier and to safeguard against proteinuria.
Acral nevus (melanocytic nevus of acral skin, melanocytic nevus with intraepidermal ascent of cells) Amelanotic blue nevus (hypomelanotic blue nevus) Balloon cell nevus Bannayan–Riley–Ruvalcaba syndrome Becker's nevus (Becker's melanosis, Becker's pigmentary hamartoma, nevoid melanosis, pigmented hairy epidermal nevus) Benign melanocytic nevus (banal nevus, common acquired melanocytic nevus, mole, nevocellular nevus, nevocytic nevus) Blue nevus (blue neuronevus, dermal melanocytoma, nevus bleu) Blue nevus of Jadassohn–Tièche (common blue nevus, nevus ceruleus) Carney complex (LAMB syndrome, NAME syndrome) Cellular blue nevus Centrofacial lentiginosis Congenital melanocytic nevus Deep penetrating nevus Dysplastic nevus (atypical mole, atypical nevus, B-K mole, Clark's nevus, dysplastic melanocytic nevus, nevus with architectural disorder) Dysplastic nevus syndrome (B-K mole syndrome, familial atypical multiple mole–melanoma syndrome, familial melanoma syndrome) Ephelis (freckle) Epithelioid blue nevus Generalized lentiginosis Giant pigmented nevus (bathing trunk nevus, congenital nevomelanocytic nevus, garment nevus, giant hairy nevus, nevus pigmentosus et pilosus) Halo nevus (leukoderma acquisitum centrifugum, perinevoid vitiligo, Sutton nevus) Hori's nevus (acquired bilateral nevus of Ota-like macules) Inherited patterned lentiginosis in black persons Ink spot lentigo (sunburn lentigo) Laugier–Hunziker syndrome Lentigo simplex (simple lentigo) Malignant blue nevus Medium-sized congenital nevocytic nevus Melanoacanthoma Melanocytic tumors of uncertain malignant potential Moynahan syndrome Mucosal lentigines (labial and penile and vulvar melanosis, melanotic macules) Nevus of Ito (nevus fuscoceruleus acromiodeltoideus) Nevus of Ota (congenital melanosis bulbi, melanosis bulborum and aberrant dermal melanocytosis, nevus fuscoceruleus ophthalmomaxillaris, oculodermal melanocytosis, oculomucodermal melanocytosis) Nevus spilus (speckled lentiginous nevus, zosteriform lentiginous nevus) Partial unilateral lentiginosis (segmental lentiginosis) Peutz–Jeghers syndrome Pigmented spindle cell nevus (pigmented spindle cell tumor of Reed, pigmented variant of Spitz nevus) Pseudomelanoma (recurrent melanocytic nevus, recurrent nevus) PUVA lentigines Small-sized congenital nevocytic nevus Spitz nevus (benign juvenile melanoma, epithelioid and spindle cell nevus, Spitz's juvenile melanoma) Solar lentigo (lentigo senilis, liver spot, old age spot, senile freckle)
=== Testosterone === Men with low levels of testosterone can experience ED. Taking testosterone may help maintain an erection. Males with type 2 diabetes are twice as likely to have lower levels of testosterone, and are three times more likely to experience ED than non-diabetic men.
The novel is permeated by poetological, often self-deprecating reflections, which are discussed in the form of possible objections Jutta or the editor might raise against the novel—and which culminate in an emphatic endorsement of the power of literature.
Sources: en.wikipedia.org
== Career and research == Dai graduated from King's College London, where he also obtained his PhD. After postdoctoral work at McMaster University, Hamilton, he moved to University of Wales Cardiff, where he progressed to a personal chair. In 1989 he moved to Swansea as Head of the Mass Spectrometry Research Unit at University of Wales, Swansea. Although best known as a mass spectrometrist and separation scientist who was the first person to bring liquid chromatography-mass spectrometry to Europe, he has made considerable contributions in organic chemistry research and served as Head of the Chemistry Department at Swansea.
=== Vaccination games === A huge literature recognizes that the vaccination can be seen as a game: in a population where everybody is vaccinated any epidemic will die off immediately so an additional person will have no interest to vaccinate at all. On the contrary, a person arriving in a population where nobody is vaccinated will have all incentives to vaccinate (the epidemic will break loose in such a population). So, it seems that the individual has interest to do the opposite of the population as a whole. But the population is the sum of all individuals, and the previous affirmation should be false. So, in fact, a Nash equilibrium is reached. Technical tools to treat such situations involve game theory or modern tools such as Mean-field game theory.
grhl2b loss causes apoptosis throughout the brain and the nervous system of zebrafish. A similar result came from a mouse study and led to the belief that grhl2b is a key survival factor for neural cells.
The proton–proton chain is more prominent in stars the mass of the Sun or less. This difference stems from temperature dependency differences between the two reactions; pp-chain reaction starts at temperatures around 4×106 K (4 megakelvins), making it the dominant energy source in smaller stars. A self-maintaining CNO chain starts at approximately 15×106 K, but its energy output rises much more rapidly with increasing temperatures so that it becomes the dominant source of energy at approximately 17×106 K. The Sun has a core temperature of around 15.7×106 K, and only 1.7% of 4He nuclei produced in the Sun are born in the CNO cycle. The CNO-I process was independently proposed by Carl von Weizsäcker and Hans Bethe in the late 1930s. The first reports of the experimental detection of the neutrinos produced by the CNO cycle in the Sun were published in 2020 by the BOREXINO collaboration. This was also the first experimental confirmation that the Sun had a CNO cycle, that the proposed magnitude of the cycle was accurate, and that von Weizsäcker and Bethe were correct.
Commercialized as the Model 470A protein sequencer, it allowed scientists to determine partial amino acid sequences of proteins that had not previously been accessible, characterizing new proteins and better understanding their activity, function, and effects in therapeutics. These discoveries had significant ramifications in biology, medicine, and pharmacology. The first automated DNA synthesizer resulted from a collaboration with Marvin H. Caruthers of the University of Colorado Boulder, and was based on Caruthers' work elucidating the chemistry of phosphoramidite oligonucleotide synthesis. Caltech staff scientist Suzanna J. Horvath worked with Hood and Hunkapiller to learn Caruthers' techniques in order to design a prototype that automated the repetitive steps involved in Caruthers' method for DNA synthesis. The resulting prototype was capable of forming short pieces of DNA called oligonucleotides, which could be used in DNA mapping and gene identification. The first commercial phosphoramidite DNA synthesizer was developed from this prototype by Applied Biosystems, who installed the first Model 380A in Caruthers' lab at the University of Colorado in December 1982, before beginning official commercial shipment of the new instrument. Revolutionizing the field of molecular biology, the DNA synthesizer enabled biologists to synthesize DNA fragments for cloning and other genetic manipulations. Molecular biologists were able to produce DNA probes and primers for use in DNA sequencing and mapping, gene cloning, and gene synthesis.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.